ESSA Pharma Correlations
| EPIX Stock | USD 1.60 0.02 1.23% |
The current 90-days correlation between ESSA Pharma and Spero Therapeutics is 0.42 (i.e., Very weak diversification). The correlation of ESSA Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
ESSA Pharma Correlation With Market
Average diversification
The correlation between ESSA Pharma and DJI is 0.12 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding ESSA Pharma and DJI in the same portfolio, assuming nothing else is changed.
ESSA |
Moving together with ESSA Stock
| 0.66 | MESO | Mesoblast | PairCorr |
| 0.64 | MGNX | MacroGenics | PairCorr |
| 0.7 | VANI | Vivani Medical Earnings Call This Week | PairCorr |
| 0.62 | CDIOW | Cardio Diagnostics | PairCorr |
Moving against ESSA Stock
| 0.39 | VALN | Valneva SE ADR | PairCorr |
| 0.36 | MLYS | Mineralys Therapeutics, Trending | PairCorr |
| 0.55 | REVBW | Revelation Biosciences | PairCorr |
| 0.35 | MRUS | Merus BV | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between ESSA Stock performing well and ESSA Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ESSA Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CYTO | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| SMMT | 4.06 | 0.30 | 0.08 | (0.78) | 4.92 | 9.31 | 30.96 | |||
| ATXI | 5.05 | (2.08) | 0.00 | 9.11 | 0.00 | 6.74 | 60.19 | |||
| SPRO | 2.57 | (0.51) | 0.00 | (1.17) | 0.00 | 4.85 | 21.98 | |||
| AGLE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
ESSA Pharma Corporate Management
| Erin Rudsinski | Executive | Profile | |
| CMA CPA | Chief Officer | Profile | |
| Terry Schuenemeyer | Executive | Profile | |
| Neil Thapar | Executive | Profile | |
| Nkengyal Barber | Executive | Profile | |
| Alessandra MD | Chief Officer | Profile |